Pheochromocytoma and Paraganglioma

Know More, Take Action

3 Unique Dimensions. 3 Actions to Take.

Tap on the bubbles
to find out more

Rare What is Pheo and Para?

Rare, but

Not Alone

Learn why connecting to a community of patients and specialized doctors matters

Distinct Symptoms and Treatment

Diverse The Genetics of Pheo and Para

A Diverse Set of

Cancer-Causing Genes

Learn how genetic testing can help identify family members at risk
Watch one person's
pheo story
References
  1. Lenders JWM, et al. J Clin Endocrinol Metab. 2014; 99(6):1915–1942.
  2. Lefebvre M, Foulkes WD. Curr Oncol. 2014;21(1):e8-e17.
  3. Gunawardane PTK, Grossman A. Adv Exp Med Biol. 2017;956:239-259.
  4. Whalen R, et al. J Urol. 1992;147(1):1-10.
  5. Scholz T, et al. J Clin Endocrinol Metab. 2007;92(4):1217-1225.
  6. Engelman K. Bull N Y Acad Med. 1969;45(9):851-858.
  7. Streby KA, et al. Pediatr Blood Cancer. 2015;62(5):5-11.
  8. Pandit-Taskar N, Modak S. J Nucl Med. 2017;58(9.2):39S-53S.
  9. Jimenez C, et al. Curr Oncol Rep. 2013;15:356-371.
  10. Eisenhofer G, et al. Endocr Relat Cancer. 2004;11:423-436.
  11. Ayala-Ramirez M, et al. J Clin Endocrinol Metab. 2011;96(3):717-725.
  12. Amar L, et al. Horm Metab Res. 2012;44(5):385-389.
  13. Kerr D. Oxford Textbook of Oncology; 2016.
  14. Martucci VL, Pacak K. Curr Probl Cancer. 2014;38(1):7-41.
  15. US Census Bureau. US and World Population Clock. https://www.census.gov/popclock/. Accessed April 1, 2019.
  16. Fishbein L. Hematol Oncol Clin North Am. 2016;30(1):135-150.
  17. American Cancer Society. Cancer Facts & Figures 2017; 2017.
  18. American Cancer Society. Cancer Facts & Figures 2019; 2019.
  19. Kirmani S, Young W. 2014.
  20. Beard CM, et al. Mayo Clin Proc. 1983;58(12):802-804.
  21. Baudin E, et al. Eur J Endocrinol. 2014;171(3):R111-R1122.
  22. Pacak K. J Clin Endocrinol Metab. 2007; 92(11):4069-4079.
  23. Phan A. Case-Based Discussion- Systemic Therapies for Advanced PHEO and PGL. In: European Society for Medical Oncology (ESMO) Congress 2014; September 26-30, 2014; Madrid, Spain.
  24. Zuber SM, et al. Endocrinol Metab Clin North Am. 2011;40(2):295-311.
  25. Erlic Z, Neumann HP. Hormones (Athens). 2009;8(1):29-38.
  26. Kantorovich V, Eisenhofer G, Pacak K. Ann N Y Acad Sci. 2009;1148:462-468.
  27. Messerli FH, et al. Am J Cardiol. 2007;99(9):1325-1329.
  28. Gruber LM, et al. J Clin Endocrinol Metab. 2019;104(5):1386-1393.
  29. Blanchet EM, et al. Front Oncol. 2012;1(58):1-9.
  30. Roman-Gonzalez A, Jimenez C. Curr Opin Endocrinol Diabetes Obes. 2017;24(3):174-183.
  31. Ajallé R, et al. Horm Metab Res. 2009;41(9):687-696.
  32. Scholten A, et al. J Clin Endocrinol Metab. 2013;98(2):581-591.
  33. NCI Dictionary of Cancer Terms. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed April 17, 2019.
  34. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Neuroendocrine and Adrenal Tumors V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed March 7, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  35. Lloyd RV, et al. WHO Classification of Tumours of the Endocrine Organs. 4th ed. 2017.
  36. Asa SL, et al. J Clin Med. 2018;7(280):1-15.
  37. Fishbein L, et al. Ann Surg Oncol. 2013;20(5):1444-1450.
  38. Remacha L, et al. Am J Hum Genet. 2019;104:651-664.
  39. Eisenhofer G, et al. Clin Biochem Rev. 2017;38(2):69-100.
  40. Brito JP, et al. Clin Endocrinol (Oxf). 2015;82(3):338-345.

NP-US-AZ-0058